Ratings Amneal Pharmaceuticals, Inc.

Equities

AMRX

US03168L1052

Real-time Estimate Cboe BZX Other stock markets 18:17:45 02/05/2024 BST			5-day change	1st Jan Change
6.255 ^USD	+2.21%		+5.51%	+2.55%

04-24	Amneal Pharmaceuticals Cleared by FDA to Sell Generic Version of Nasal Spray to Treat Opioid Overdose -- Shares Rise	MT
04-24	Amneal Pharmaceuticals Shares Rise 9% After FDA Approves Naloxone Spray	DJ

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

The company has a low valuation given the cash flows generated by its activity.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
Over the past four months, analysts' average price target has been revised upwards significantly.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

Low profitability weakens the company.
One of the major weak points of the company is its financial situation.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 122.4 times its estimated earnings per share for the ongoing year.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
AMNEAL PHARMACEUTICALS, INC.	+2.55%	1.89B	C-
ELI LILLY AND COMPANY	+30.01%	699B	C+
NOVO NORDISK A/S	+25.07%	571B	B
JOHNSON & JOHNSON	-4.70%	364B	C+
MERCK & CO., INC.	+18.03%	326B	B-
ABBVIE INC.	+2.76%	286B	C+
ASTRAZENECA PLC	+14.68%	236B	B+
NOVARTIS AG	+4.71%	198B	B-
ROCHE HOLDING AG	-12.43%	194B	A+
PFIZER, INC.	-3.35%	154B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes